Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by IVUS (IntraVascular UltraSounds), in Overweight Patients With Clustering Risk Factors.

Trial Profile

Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by IVUS (IntraVascular UltraSounds), in Overweight Patients With Clustering Risk Factors.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Obesity
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms STRADIVARIUS
  • Most Recent Events

    • 02 Apr 2008 Results published in JAMA and presented at ACC 2008
    • 12 Feb 2008 According to a media release by sanofi-aventis, results will be presented at the 57th Annual Scientific Sessions of the American College of Cardiology, held in Chicago, Illinois, USA from 29 March - 1st April 2008.
    • 26 Nov 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top